Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Mucocele After Orbital Fracture Repair Masquerading as Optic Neuritis.
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
The Characteristics of Multiple Sclerosis in Iran.
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
Vitamin D and autoimmunity.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
Epidemiology of Multiple Sclerosis in Latin America: Critical Analysis of the Literature.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Consent guidance: patients and doctors making decisions together
The enigma of ceramide synthase regulation in mammalian cells.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Pediatric Lyme Neuroborreliosis: Different clinical presentations of the same agent; Single center experience.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Effirma, Synthetic Biologics